The decision by CMS marks a significant milestone in the recognition of the value and effectiveness of Aquadex SmartFlow ultrafiltration therapy for treating fluid overload in heart failure patients.
Nuwellis, Inc. is a medical device company ... through innovative ultrafiltration therapies. Based in Minneapolis, the company focuses on commercializing the Aquadex SmartFlow system for both ...
Stocktwits on MSN1mon
Nuwellis Stock Spikes After Reimbursement Hike: Retail’s UpbeatShares of medical device ... for its ultrafiltration therapy, lifting retail sentiment. Effective January 1, 2025, the ...
Nuwellis is a medical device company that specializes in producing the Aquadex SmartFlow system to do the ultrafiltration procedure for patients with fluid overload. Ultrafiltration process is used ...
“We commend the hard work and dedication of the Nuwellis team, fueling steady market adoption of our Aquadex ultrafiltration therapy ... Investors page at https://ir.nuwellis.com. The Aquadex ...
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company committed to ... recognition of the value and effectiveness of Aquadex SmartFlow ...
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated ... The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback